Danish drugmaker Novo Nordisk's India Head, Vikrant Shrotiya, shares that the pharmaceutical giant is ready to launch Ozempic ...

Novo Nordisk confirms the upcoming India launch of Ozempic, its once-weekly semaglutide injection for Type 2 diabetes and ...

Telehealth firm LifeMD said on Tuesday it would partner with Novo Nordisk to offer its diabetes drug Ozempic at $499 per ...

LifeMD (LFMD) stock is in focus as the firm expands its telehealth collaboration with Novo Nordisk to offer the pharma ...

LifeMD’s telehealth platform is seamlessly integrated with NovoCare ® Pharmacy to provide easy, reliable access to Novo Nordisk’s FDA-approved GLP-1 medications, Ozempic ® and Wegovy ®, at the most ...

The Central Drugs Standard Control Organisation has approved Novo Nordisk's Ozempic, a groundbreaking once-a-week injection ...

Morgan Stanley has downgraded Novo Nordisk, whose U.S. shares are already down a third this year. That downgrade forecasts ...

Morgan Stanley analyst Thibault Boutherin pointed to slowing momentum in U.S. prescriptions for Novo's flagship GLP-1 drugs, ...

Danish pharmaceutical company Novo Nordisk, the maker of blockbuster drugs Ozempic and Wegovy, is planning job cuts at its Irish operation.

Novo Nordisk has received CDSCO approval for its blockbuster drug Ozempic, completing its semaglutide portfolio in India as ...

Novo Nordisk stock fell after Morgan Stanley said Ozempic and Wegovy prescription growth is stagnating, and recommended ...

(Reuters) -Telehealth firm LifeMD said on Tuesday it would offer Danish drugmaker Novo Nordisk's diabetes drug Ozempic at $499 per month to eligible U.S. patients. Eligible self-pay and uninsured ...